Monoclonal antibody · Antagonist of sclerostin (SOST) · developed by Ultragenyx Pharmaceutical
Setrusumab is a fully human monoclonal antibody that neutralizes sclerostin, a protein that inhibits bone formation. It is administered by intravenous infusion and is studied in osteogenesis imperfecta, osteopenia and osteoporosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06636071 | Phase 3 | Osteogenesis Imperfecta | Active not recruiting | RARE |
| NCT05125809 | Phase 2/3 | Osteogenesis Imperfecta | Active not recruiting | MREO |
| NCT03216486 | Phase 2 | Osteogenesis Imperfecta | Withdrawn | MREO |
| NCT01406548 | Phase 2 | Osteopenia | Completed | MREO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Osteogenesis ImperfectaOsteopeniaOsteoporosis
Updated Oct 25, 2026. Something wrong or missing? Report it on the RARE page.
See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RARE catalysts and pipeline →